S-Adenosyl Methionine
14 benefits mapped to clinical evidence across supplements.
Dose per serving from products
109 products in our catalogue print how much S-Adenosyl Methionine a serving holds.
Most common: 250 mg to 500 mg, 34% of 109 products.
| Dose per serving | Products |
|---|---|
| 25 mg or less | 6 |
| 25 mg to 50 mg | 21 |
| 50 mg to 100 mg | 11 |
| 100 mg to 250 mg | 34 |
| 250 mg to 500 mg | 37 |
Dose per serving from research
22 study groups in 18 studies say how much S-Adenosyl Methionine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 g to 2.5 g, 55% of 22 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 3 |
| 500 mg to 1 g | 4 |
| 1 g to 2.5 g | 12 |
| over 2.5 g | 1 |
Benefit Evidence
Depression severity, response/remission
-18.5pp response; +14.1pp remission
Earlier mood improvement
Depression severity, response/remission
-18.5pp response; +14.1pp remission
Earlier mood improvement
Research sources
Pain relief (11)
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]
PubMed ID: 15102339
Knee OA trial: SAMe reduced pain comparably to celecoxib by 8 weeks (symptomatic relief).
- A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis
PubMed ID: 14687046
In ICP SAMe significantly improved pruritus (itching) compared with baseline (symptomatic relief).
- [Ursodeoxycholic acid, S-adenosyl-L-methionine and their combinations in the treatment of gestational intrahepatic cholestasis (ICP)]
PubMed ID: 16649407
Confirms pruritus improvement with SAMe in ICP, though biochemistry less affected.
- [A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis]
PubMed ID: 10880165
Ademetionine relieved itching and improved biochemical cholestasis measures more than comparator.
- Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
PubMed ID: 2188871
Large cholestasis trial reported significant improvement in pruritus and fatigue vs placebo.
- S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial
PubMed ID: 2083923
IV SAMe reduced pruritus significantly in ICP trial.
- [Analysis on therapeutic effect of Western and Chinese drug in treating intrahepatic cholestasis pregnancy]
PubMed ID: 15143715
ICP comparison found SAMe reduced pruritus and improved liver tests similar to a Chinese decoction.
- Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients
PubMed ID: 20110025
Korean OA RCT: SAMe reduced knee pain similarly to nabumetone over 8 weeks.
- Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study
PubMed ID: 32589828
Combined SAMe + probiotic product improved depression/anxiety symptoms faster than placebo, reducing emotional distress (combination product).
- Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial
PubMed ID: 36411659
SAMe + probiotic supplement produced clinically meaningful reductions in depression scores (reduced psychological discomfort).
- A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy
PubMed ID: 9853771
SAMe (alone and especially with UDCA) improved itching in intrahepatic cholestasis of pregnancy.
Mood balance (9)
- S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial
PubMed ID: 20595412
Randomized double‑blind adjunctive SAMe significantly improved depression response and remission rates versus placebo.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies
PubMed ID: 12418499
Two large multicenter trials showed SAMe performed similarly to imipramine for major depression with fewer side effects.
- S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial
PubMed ID: 31712971
Pilot RCT of SAMe 800 mg/day showed a clinically meaningful (though NS) benefit overall and significant benefit in milder depression subgroup.
- Efficacy of a food supplement based on S-adenosyl methionine and probiotic strains in subjects with subthreshold depression and mild-to-moderate depression: A monocentric, randomized, cross-over, double-blind, placebo-controlled clinical trial
PubMed ID: 36411659
Randomized placebo‑controlled trial of a supplement containing SAMe + probiotic produced significant reductions in depression scores vs placebo.
- Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study
PubMed ID: 32589828
Combined SAMe + probiotic product reduced depression and anxiety symptoms faster than placebo, supportive for emotional balance though combination confounds attribution.
- S-adenosyl methionine (SAMe) versus escitalopram and placebo in major depression RCT: efficacy and effects of histamine and carnitine as moderators of response
PubMed ID: 24856557
Site-specific analysis found SAMe produced larger and earlier antidepressant effects vs placebo and escitalopram with notable response/remission differences—robust clinical signal.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder
PubMed ID: 12466028
Multicenter IM SAMe vs imipramine trial (n≈293) demonstrated comparable efficacy and superior tolerability.
- Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine
PubMed ID: 1289923
Adjunctive SAMe accelerated onset of tricyclic antidepressant action in depressed outpatients.
- Double-blind, placebo-controlled study of S-adenosyl-L-methionine in depressed postmenopausal women
PubMed ID: 8441793
Randomized double-blind trial in depressed postmenopausal women demonstrating significant and relatively rapid mood improvement.
Liver support (9)
- [The results of phase III multicenter open randomized controlled study REM-Chol-III-16 in patients with intrahepatic cholestasis syndrome caused by chronic diffuse liver diseases]
PubMed ID: 36286675
Phase III trial showed Remaxol non‑inferior to parenteral SAMe (Heptral) on cholestasis labs/symptoms, indicating parenteral SAMe has short‑term liver benefit comparators.
- A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy
PubMed ID: 9853771
ICP trial where SAMe (especially combined with UDCA) improved itching and liver tests versus placebo.
- Beneficial effects of S-adenosyl-L-methionine on post-hepatectomy residual liver function: a prospective, randomized, controlled clinical trial
PubMed ID: 23491928
Post-hepatectomy IV SAMe reduced postoperative liver dysfunction in patients with significant ischemia—clinical RCT subgroup evidence of hepatic protection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
PubMed ID: 10406187
Two‑year RCT in alcoholic cirrhosis reduced death/transplant in less-advanced disease and improved liver outcomes.
- S-adenosylmethionine for the treatment of intrahepatic cholestasis of pregnancy. Results of a controlled clinical trial
PubMed ID: 2083923
ICP trial showed IV SAMe reduced bile acids, bilirubin, aminotransferases and pruritus vs placebo.
- Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
PubMed ID: 2188871
Large RCT in chronic cholestasis showed significant improvements in bilirubin, ALP and pruritus versus placebo.
- Effects of S-adenosyl-L-Methionine Combined with Ursodesoxycholic Acid on Serum Endotoxin, MMP-9 and IL-18 in Neonates with Cholestasis
PubMed ID: 34794285
Neonatal RCT: adding SAMe to UDCA improved inflammatory/endotoxin markers and overall response rate in cholestatic neonates — direct positive liver support evidence.
- [Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases]
PubMed ID: 8679834
RCT in alcoholic liver disease found increased glutathione, decreased lipid peroxidation and improved clinical/biochemical indices vs placebo.
- [A trial of ademetionine in the treatment of intrahepatic biliary stasis viral hepatitis]
PubMed ID: 10880165
Randomized study in cholestatic viral hepatitis reported symptomatic and laboratory advantages for ademetionine.
Detoxification (6)
- Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease
PubMed ID: 7811344
Restoration of erythrocyte glutathione in alcoholic patients supports a role in antioxidant/detox pathways.
- [Parenteral S-adenosylmethionine compared to placebos in the treatment of alcoholic liver diseases]
PubMed ID: 8679834
Decreased lipid peroxidation and increased glutathione in alcoholic liver disease indicate detox/antioxidant benefit.
- Lowering plasma S-Adenosylhomocysteine (SAH) in healthy adults with elevated SAH and normal homocysteine using nutritional supplementation
PubMed ID: 40883125
Supplement lowered SAH and increased SAM:SAH ratio, improving methylation potential which supports xenobiotic methylation/detox pathways indirectly.
- Metabolic Signature of Arsenic Exposure and Metabolism: The Folic Acid and Creatine Trial
PubMed ID: 40668877
Large arsenic‑exposed RCT: folic acid (one‑carbon nutrition) altered arsenic methylation and related metabolomic pathways — strong evidence that supporting methylation aids detoxification of arsenic.
- Effects of S-adenosyl-L-Methionine Combined with Ursodesoxycholic Acid on Serum Endotoxin, MMP-9 and IL-18 in Neonates with Cholestasis
PubMed ID: 34794285
SAMe + UDCA reduced endotoxin and inflammatory markers in neonatal cholestasis — relevant to clearance/ detoxification processes in liver disease.
- Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
PubMed ID: 2188871
Improvements in cholestasis biomarkers suggest enhanced biliary/excretory homeostasis (detoxification).
Vitality (4)
- Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
PubMed ID: 2188871
Large chronic cholestasis RCT improved lab and symptoms including fatigue, reflecting improved vitality.
- Lowering plasma S-Adenosylhomocysteine (SAH) in healthy adults with elevated SAH and normal homocysteine using nutritional supplementation
PubMed ID: 40883125
Placebo‑controlled trial lowered SAH and improved SAM:SAH ratio, indicating improved methylation capacity that could underlie broad vitality effects.
- Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial
PubMed ID: 33749643
Folic acid increased SAM and improved biomarkers/cognition in MCI, consistent with improved systemic function that may map to overall vitality.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial
PubMed ID: 10406187
Two‑year RCT in alcoholic cirrhosis reduced death/transplant in less-advanced disease—supports clinically meaningful improved vitality/survival.
Metabolism (3)
- Metabolic Signature of Arsenic Exposure and Metabolism: The Folic Acid and Creatine Trial
PubMed ID: 40668877
Large trial showed one‑carbon metabolites (SAM/SAH) and folic acid supplementation altered arsenic metabolism and systemic metabolome — supports role in metabolic balance.
- Choline intake exceeding current dietary recommendations preserves markers of cellular methylation in a genetic subgroup of folate-compromised men
PubMed ID: 20220206
Choline intake preserved plasma SAM and reduced DNA methylation loss in folate‑compromised men; strong mechanistic relevance to methylation/metabolic balance.
- Impact of the MTHFR C677T polymorphism on one-carbon metabolites: Evidence from a randomised trial of riboflavin supplementation
PubMed ID: 32330571
Riboflavin increased SAM in MTHFR 677TT individuals, demonstrating genotype‑specific modulation of one‑carbon metabolism.
Focus & concentration (3)
- Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial
PubMed ID: 33749643
Folic acid (±DHA) raised SAM and reduced amyloid markers and improved some cognitive tests in MCI — strong indirect support for cognitive focus.
- Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial
PubMed ID: 29255930
Large folic‑acid RCT in MCI increased SAM and improved multiple cognitive domains — supports improved cognitive focus via methylation.
- Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial
PubMed ID: 27340344
Alzheimer patients on donepezil plus folic acid showed improved SAM and small cognitive gains (supportive, but confounded).
Memory (3)
- Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial
PubMed ID: 29255930
Large 24‑month RCT: folic acid increased SAM and improved multiple cognitive tests in MCI — strong indirect support for methylation‑mediated memory benefits.
- Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial
PubMed ID: 27340344
Alzheimer patients receiving folic acid had increased SAM and modest cognitive improvements while on donepezil (supportive but confounded).
- Effects of Folic Acid Combined with DHA Supplementation on Cognitive Function and Amyloid-β-Related Biomarkers in Older Adults with Mild Cognitive Impairment by a Randomized, Double Blind, Placebo-Controlled Trial
PubMed ID: 33749643
RCT in older adults with MCI: folic acid raised SAM, lowered homocysteine and Aβ markers and improved some cognitive scores over 6 months.
Mental clarity (2)
- Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial
PubMed ID: 27340344
Alzheimer patients on donepezil plus folic acid showed increases in SAM and small cognitive improvements (supports methylation‑related cognitive effects).
- Effects of folic acid supplementation on cognitive function and Aβ-related biomarkers in mild cognitive impairment: a randomized controlled trial
PubMed ID: 29255930
24‑month folic‑acid RCT in MCI raised SAM and improved multiple cognitive domains, supporting clearer cognition (indirect evidence for methylation pathway).
Joint comfort (2)
- Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients
PubMed ID: 20110025
Korean RCT: SAMe (1200 mg/day) reduced knee OA pain similarly to nabumetone over 8 weeks.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]
PubMed ID: 15102339
Randomized trial: SAMe produced pain/function benefits similar to celecoxib by 8 weeks (slower onset).
Joint mobility (2)
- Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, Phase IV study in Korean patients
PubMed ID: 20110025
Korean knee OA trial: SAMe reduced pain and improved function similar to nabumetone.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495]
PubMed ID: 15102339
Knee OA RCT: SAMe improved pain and function to levels comparable to celecoxib by 8 weeks, supporting mobility.
Energy & Fatigue (1)
- Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. A double-blind, placebo-controlled study
PubMed ID: 2188871
Cholestasis trial reported improved fatigue and symptoms, suggesting increased energy levels.
Illness recovery (1)
- Effects of S-adenosyl-L-Methionine Combined with Ursodesoxycholic Acid on Serum Endotoxin, MMP-9 and IL-18 in Neonates with Cholestasis
PubMed ID: 34794285
Neonatal cholestasis: SAMe + UDCA improved inflammatory/endotoxin markers and overall response rate over 10 days (faster clinical response).
Immune support (1)
- Effects of S-adenosyl-L-Methionine Combined with Ursodesoxycholic Acid on Serum Endotoxin, MMP-9 and IL-18 in Neonates with Cholestasis
PubMed ID: 34794285
Neonatal RCT: adding SAMe to UDCA lowered endotoxin, IL-18 and MMP-9, indicating anti‑inflammatory/immune‑modulating effects.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with S-Adenosyl Methionine
Search all152 products whose verified label declares S-Adenosyl Methionine — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.